The subject of trastuzumab deruxtecan package insert encompasses a wide range of important elements. label - Food and Drug Administration. In order to prevent medication errors, check the vial labels to ensure that the drug being prepared and administered is ENHERTU (fam-trastuzumab deruxtecan-nxki) and not trastuzumab or... HIGHLIGHTS OF PRESCRIBING INFORMATION .... For injection: 100 mg of fam-trastuzumab deruxtecan-nxki as a white to yellowish white lyophilized powder in a single-dose vial for reconstitution and further dilution Moreover, enhertu: Package Insert / Prescribing Information / MOA. ENHERTU® - AstraZeneca US.
The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. Product Monograph Including Patient Medication Information. deruxtecan or its metabolites are found in seminal fluid.
Before starting treatment, male pati nts should be advised to seek counseling on sperm storage. Male patients must not freeze or donate sperm throughout the treatment period, Enhertu (trastuzumab deruxtecan) [package insert]. Approved indications from this document for cancer drugs containing at least one biomarker. Enhertu (Daiichi Sankyo Inc.): FDA Package Insert.
ENHERTU is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
📝 Summary
Throughout this article, we've investigated the different dimensions of trastuzumab deruxtecan package insert. These insights not only inform, but also help you to take informed action.